Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage biopharmaceutical company. Inovio develops deoxyribonucleic acid (DNA)-based vaccines and immune therapies, called synthetic vaccines, in combination with electroporation delivery devices to prevent and treat cancers and infectious diseases. Inovio’s synthetic vaccines are based on the Company’s SynCon vaccine design. The Company has completed, current or planned clinical programs of its SynCon vaccines and immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, malaria and Ebola. The synthetic vaccine platform comprises the Company’s SynCon vaccine design process as well as its electroporation delivery technology. Inovio has developed a pre-clinical and clinical-stage pipeline of products.